Stock AnalizCareDx, Inc. CDNA
Medical Specialities · IPO 2014 · data as of November 13, 2026
CareDx, Inc. (CDNA) is a healthcare company listed in the US with a market value of about $4.1B. In the twelve months to September 30, 2026 it had revenue of $497M and net income of $129M, a net margin of 25.9%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a P/E of 32.6, a price to free cash flow of 68.5, 5-year revenue growth of 15% a year, a 5-year average ROIC of -14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 78% below the current price.
Score: 1.6 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $497M | $380M | $334M | $280M | $322M | $296M | $192M | $127M | $77M | $48M |
| Net income | $129M | -$21M | $53M | -$190M | -$77M | -$31M | -$19M | -$22M | -$47M | -$55M |
| Free cash flow | $60M | — | — | — | — | — | — | — | -$6M | -$14M |
| EPS (diluted) | $2.39 | $-0.40 | $0.93 | $-3.54 | $-1.44 | $-0.59 | $-0.40 | $-0.52 | $-1.31 | $-2.38 |
| Net margin | 25.9% | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% | -9.7% | -17.3% | -61.1% | -114.8% |
| ROIC | — | -7.4% | 10.0% | -54.4% | -13.0% | -5.8% | -7.2% | -21.6% | -15.8% | -70.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $94.43, 21% above the current price; targets range from $90.00 to $100.00; the consensus rating is “Buy”; expected EPS is $1.78 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is CareDx’s P/E ratio?
About 32.6, based on the last twelve months of diluted earnings per share (forward P/E about 53.7).
Is CareDx stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 78% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does CareDx pay a dividend?
Not currently.
Is CareDx a good stock to buy?
We do not give buy or sell advice. CareDx scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.